Editing RNA to rewrite the future of medicine
Korro Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA. By leveraging endogenous RNA editing mechanisms, Korro's platform enables treatment of both rare and highly prevalent diseases. The company's lead program KRRO-110 targets alpha-1 antitrypsin deficiency (AATD). Founded in 2019 out of Atlas Venture, Korro merged with Frequency Therapeutics in 2023 and listed on Nasdaq (KRRO).
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account